CLEO Diagnostics Ltd (AU:COV) has released an update.
CLEO Diagnostics Ltd has partnered with Lindus Health, a specialist in med-tech clinical trials, to manage U.S. testing of its innovative ovarian cancer blood test, aimed at obtaining FDA approval. The upcoming trial will recruit up to 500 patients and is crucial for CLEO’s U.S. market entry strategy. This collaboration promises to streamline the trial process and enhance the company’s efforts to improve health outcomes for women with ovarian cancer.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.
